2022
Daily Rapid Antigen Exit Testing to Tailor University COVID-19 Isolation Policy - Volume 28, Number 12—December 2022 - Emerging Infectious Diseases journal - CDC
Earnest R, Chen C, Chaguza C, Hahn A, Grubaugh N, Wilson M, . Daily Rapid Antigen Exit Testing to Tailor University COVID-19 Isolation Policy - Volume 28, Number 12—December 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 2455-2462. PMID: 36417936, PMCID: PMC9707582, DOI: 10.3201/eid2812.220969.Peer-Reviewed Original Research
2020
Hypervirulent pneumococcal serotype 1 harbours two pneumolysin variants with differential haemolytic activity
Panagiotou S, Chaguza C, Yahya R, Audshasai T, Baltazar M, Ressel L, Khandaker S, Alsahag M, Mitchell TJ, Prudhomme M, Kadioglu A, Yang M. Hypervirulent pneumococcal serotype 1 harbours two pneumolysin variants with differential haemolytic activity. Scientific Reports 2020, 10: 17313. PMID: 33057054, PMCID: PMC7560715, DOI: 10.1038/s41598-020-73454-w.Peer-Reviewed Original ResearchConceptsPneumococcal serotype 1Invasive pneumococcal diseaseSerotype 1Haemolytic activityVivo mouse modelDetectable haemolytic activityNeutrophil-mediated phagocytosisPneumococcal diseaseCommon causeInfection doseHuman reservoirMouse modelRapid onsetStreptococcus pneumoniaeDisease symptomsLethal doseClonal typesVirulence propertiesGlobal pathogenST306IgA proteaseSymptomsSequence typesMiceDose